Artemis Medicare Services: Monitoring Agency Report for Q4FY26
Artemis Medicare Services Limited filed its Monitoring Agency Report for Q4FY26. The report covers the utilization of ₹330 crore from a Preferential Issue. During the quarter, ₹474.62 crore was utilized, including ₹54 crore for expansion and ₹74.62 crore as an advance revenue share. ₹193.11 crore remains unutilized.
This is a standard compliance filing related to the utilization of previously raised funds. It does not introduce new financial information or strategic directives that would immediately affect the company's stock price or operational trajectory.
The report is a routine regulatory filing and does not contain any new financial performance data or strategic announcements that would significantly impact the company's outlook. It confirms adherence to the utilization of funds from a previous issuance.
Artemis Medicare Services Limited has submitted its Monitoring Agency Report for the quarter ended March 31, 2026. The report, issued by CARE Ratings Limited, details the utilization of proceeds from a Preferential Issue amounting to ₹330 crore.
This report was reviewed by the Audit Committee on May 8, 2026, and is also available on the company's website. The monitoring agency confirmed that the utilization of funds is in line with the objects disclosed in the Offer Document. During Q4FY26, the company utilized ₹474.62 crore. Specifically, ₹54.00 crore was utilized for acquisition, expansion, and capital expenditure, and an additional advance revenue share of ₹74.62 crore was paid under a Medical Service Agreement with Ar Vidhyasagar Kaushalya Devi Memorial Health Centre.
No funds were utilized for general corporate purposes during the quarter. The total utilization as of March 31, 2026, stands at ₹136.89 crore, with ₹193.11 crore remaining unutilized. The unutilized proceeds are invested in fixed deposits with various banks, maturing between April 2026 and November 2026.
What to do with a filing like this
Artemis Medicare Services Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Artemis Medicare Services Limited. Read the original for the full detail.